Ascenta Capital Announces $325M Inaugural Fund

Gunderson Dettmer represented client Ascenta Capital, a venture firm investing in multi-medicine development-stage biotechnology companies, in the formation of its $325 million inaugural fund.

To date, Ascenta has deployed more than $100 million of capital into six biotech companies that, collectively, are active in 14 clinical trials and have more than 40 pipeline programs. 

In the announcement of the fund, Ascenta co-founder Dr. Evan Rachlin said, “Ascenta pursues an intentionally selective investment strategy founded on deep relationships. By focusing on a small number of exceptional biotechs, we can concentrate our thought-partnership on clinical, regulatory, manufacturing, scientific, and capital strategy” and Ascenta co-founder Dr. Lorence Kim said “We take a deliberate approach with every one of our portfolio companies, who understand that we don’t want to simply act as a financial partner.”

The Gunderson deal team was led by Nick Guttilla and Emily O’Brien and included Sarah Anischik, Blake Rowe and Remy Altman.

Companies
Ascenta